Regencell Bioscience Holdings Limited Ordinary Shares (RGC)
StalwartFairStock Score: 23/100 — RISKY
Key Financials
| Current Price | $28.58 |
| Market Cap | $13.9B |
| P/E Ratio | -2,858 |
| ROE | -177.66% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Conservative balance sheet with debt-to-equity of just 0.11, providing financial flexibility
AI Analysis
Regencell Bioscience Holdings Limited Ordinary Shares is a mid-cap healthcare company valued at $13.9 billion. From a quality standpoint, Regencell shows negative ROE indicating losses and conservative leverage at 0.11x debt-to-equity. Our composite FairStock Score of 23/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer